Laura Andrea
Charola Ramos
Investigadora en el periodo 2018-2021
Hospital Universitario Nuestra Señora de Candelaria
Santa Cruz de Tenerife, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Nuestra Señora de Candelaria (16)
2023
-
Hematological Composite Scores in Patients with Inflammatory Bowel Disease
Journal of Clinical Medicine, Vol. 12, Núm. 23
-
Serum Levels of Lipoprotein Lipase Are Increased in Patients with Inflammatory Bowel Disease
International journal of molecular sciences, Vol. 24, Núm. 6
2022
-
Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease
Clinical and translational gastroenterology, Vol. 13, Núm. 6, pp. e00500
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection
Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 668-676
-
Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Carotid plaque assessment reclassifies patients with inflammatory bowel disease into very-high cardiovascular risk
Journal of Clinical Medicine, Vol. 10, Núm. 8
-
Diet and microbiome in the beginning of the sequence of gut inflammation
World Journal of Clinical Cases, Vol. 9, Núm. 36, pp. 11122-11147
-
Insulin resistance is not increased in inflammatory bowel disease patients but is related to non-alcoholic fatty liver disease
Journal of Clinical Medicine, Vol. 10, Núm. 14
-
Qrisk3 performance in the assessment of cardiovascular risk in patients with inflammatory bowel disease
Journal of Clinical Medicine, Vol. 10, Núm. 18
2020
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
-
Factores predictores de la respuesta clínica al tratamiento con anti-TNF en colitis ulcerosa: ¿qué hemos aprendido de nuestros pacientes?
Revista Espanola de Enfermedades Digestivas, Vol. 112, Núm. 8, pp. 636-641